Teva Pharmaceutical Industries Ltd ADR Stock
There is an upward development for Teva Pharmaceutical Industries Ltd ADR compared to yesterday, with an increase of €0.30 (1.150%).
With 22 Buy predictions and not a single Sell prediction Teva Pharmaceutical Industries Ltd ADR is an absolute favorite of our community.
With a target price of 31 € there is a slightly positive potential of 16.1% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 26.7 €.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | 1.150% | -1.838% | 6.800% | 103.817% | -0.743% | 245.855% | 210.827% |
| Bayer AG ADR | -3.570% | -9.135% | -2.073% | 68.750% | 7.386% | -35.714% | -30.515% |
| Roche Holding AG ADR | -0.600% | 0.176% | 4.277% | 25.596% | -0.314% | 24.530% | 26.205% |
| Novartis AG ADR | -1.600% | -3.876% | -3.876% | 25.506% | 4.641% | 33.047% | 72.702% |
Comments
Teva Pharmaceutical Industries (TEVA) had its price target raised by Bank of America Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (TEVA) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $41.00 price target on the stock, up from $40.00.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat